Home>Topics>Stocks>Novo Nordisk A>Novo Nordisk A/S ADR

Novo Nordisk A/S ADR NVO

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. FDA accepts Lilly's NDA for type 2 diabetes combo

      Headlines

      Tue, 21 Oct 2014

      for many years. Diabetes-related tickers: ( JNJ +0.4% )( OTCQB:ISLT )( OTCQB:BTHE +20% )( VTAE +2.5% )( NVO +0.5% )( MRK +0.9% )(NASDAQ: VKTX )( HPTX +0.4% )( ABT +1.2% )( OTCPK:TKPHF )( OTCPK:TKPYY -0

    2. What To Watch For As Orexigen's Launch Approaches

      Headlines

      Thu, 16 Oct 2014

      VVUS ) as one of three companies with FDA approved anti-obesity drugs on the market. Other players looking to enter the space are Novo Nordisk (NYSE: NVO ) and Zafgen (NASDAQ: ZFGN ). All will have a presence at Obesity Complete Story »

    3. China Biologic Presents A Unique Investment Opportunity

      Headlines

      Mon, 22 Sep 2014

      By Trevor Lowenthal : China Biologic Products (NASDAQ: CBPO ) is a biopharmaceutical company focused on marketing plasma-based products to China. China Biologic has displayed strong successive earnings growth over the past two quarters as it continues to bear the fruits from its efforts to raise ...

    4. EC clears Xultophy

      Headlines

      Fri, 19 Sep 2014

      The European Commission approves Novo Nordisk's (NYSE: NVO ) Xultophy for the treatment of adult patients with type 2 diabetes to improve glycemic control in combination with oral glucose-lowering

    5. Novo's Ryzodeg provides glycemic control with fewer injections but fails in Phase 3 trial

      Headlines

      Thu, 18 Sep 2014

      In a Phase 3b clinical trial , Novo Nordisk's (NYSE: NVO ) Ryzodeg (insulin degludec/insulin aspart) administered twice daily provided successful glycemic control with fewer injections

    6. Sanofi: Stiff Competition Will Impact Future Performance

      Headlines

      Wed, 17 Sep 2014

      By Investing Tricks : Sanofi's (NYSE: SNY ) revenues are distributed through three major segments and a large chunk is attributable to the pharmaceutical segment; 85% of revenues are attributed to the pharmaceutical segment. More than half the pharmaceutical revenues are drawn from the US and ...

    7. Orexigen Therapeutics Wins Contrave Approval But Investors Should Stay Away

      Headlines

      Tue, 16 Sep 2014

      By Long Term Bio : Orexigen Therapeutics (NASDAQ: OREX ) received FDA approval for their obesity drug Contrave on September 10th, 2014. The FDA has finally determined that Contrave is a safe obesity drug to give to patients to help reduce their weight. Orexigen Therapeutics has been struggling to

    8. New Diabetes Drugs Gain Approval - Florins Versus Oral Insulin

      Headlines

      Sun, 14 Sep 2014

      By Sharon di Stefano : Pharmaceutical companies are adept at rolling out new classes of drugs, despite potential harmful side effects, and Eli Lilly and Co. (NYSE: LLY ) is no exception. Just recently, Lilly began selling Jardiance, a once-daily tablet for Type 2 diabetics, a 'flozin', with an ...

    9. Novo Gets Positive Vote From FDA For Anti-Obesity Treatment - Still A Long Road Ahead

      Headlines

      Fri, 12 Sep 2014

      By Spencer Osborne : Novo Nordisk (NYSE: NVO ) received good news earlier this week in its quest to get an obesity indication for its drug Saxenda. The drug is a different

    10. Ad Comm gives thumbs up to Novo's obesity drug candidate

      Headlines

      Thu, 11 Sep 2014

      The FDA's Endocrinologic and Metabolic Drugs Advisory Committee concludes that Novo Nordisk's ( NVO +1.8% ) obesity drug Saxenda (liraglutide) is safe and effective enough to warrant approval . Post your comment!

    « Prev12345Next »
    Content Partners